Biotech is about to change your world

Summary

TED Radio Hour Episode Summary: "Biotech is About to Change Your World"

Released April 18, 2025 | Host: Manoush Zomorodi | Produced by NPR

---

Introduction: The Dawn of a Biotechnological Revolution

In this captivating episode of the TED Radio Hour, host Manoush Zomorodi delves into the groundbreaking advancements in biotechnology that are poised to transform various facets of our lives. From mapping every cell in the human body to engineering climate-resilient crops, the episode explores how innovative biotech tools like CRISPR and artificial intelligence are reshaping medicine, agriculture, and environmental sustainability.

---

Mapping the Blueprint of Life: The Human Cell Atlas with Aviv Regev

Aviv Regev, a computational biologist and co-founder of the Human Cell Atlas project, shares her vision of revolutionizing personalized medicine through detailed cellular mapping.

• Breakthroughs from the Human Genome Project: Regev begins by reflecting on the completion of the Human Genome Project 25 years ago, emphasizing its role in advancing cancer treatments and understanding rare diseases. However, she points out that the static nature of the genome map is just the beginning.

  “My cells today are not the same as the cells that I had 20 years ago or the cells I will have in 20 years from now.” (02:05)

• Dynamic Cellular Mapping: The Human Cell Atlas aims to catalog every type of cell in the human body, capturing their changes and interactions over time. Regev explains how this dynamic map is akin to a constantly updating Google Maps for the human body, enabling highly targeted medical treatments.

  “It's the things we need in order to navigate the human body. If I want to develop a medicine that would only go to the place where something is broken... I need to know how to get there.” (04:11)

• AI Integration in Medicine: Leveraging artificial intelligence, Regev discusses how the Human Cell Atlas facilitates the identification of specific cells for targeted therapies, significantly improving the drug development process. This integration reduces the failure rate of potential drugs, which traditionally stands at 90%.

  “We absolutely have to do better than that.” (07:47)

• Personalized Cancer Vaccines: A standout innovation highlighted is the development of personalized cancer vaccines. By sequencing a patient’s tumor and identifying unique mutations, scientists can create vaccines tailored to trigger the immune system specifically against cancer cells in that individual.

  “Highly personalized medicine that the cancer patient can receive after their diagnosis.” (12:36)

• Preventative Medicine: Looking ahead, Regev envisions a future where diseases can be predicted and prevented before they manifest, using genetic and cellular blueprints established at birth.

  “Preventative disease treatment that today is simply not possible... because we can nip them in the bud.” (16:40)

---

Revolutionizing Agriculture with CRISPR: Insights from Brad Ringisen

Brad Ringisen, a physical chemist and head of the Innovative Genomics Institute (IGI), explores the transformative potential of the gene-editing tool CRISPR in agriculture and climate resilience.

• CRISPR vs. Traditional GMOs: Ringisen differentiates CRISPR from traditional genetically modified organisms (GMOs), highlighting its precision in editing specific genes without introducing uncontrolled genomic changes.

  “CRISPR is a tremendously precise tool... changing one gene.” (22:39)

• Climate-Resilient Crops: The IGI is actively developing crops that can withstand extreme weather conditions exacerbated by climate change. Examples include flood-tolerant rice and drought-resistant crops, which promise to secure food supplies in vulnerable regions.

  “CRISPR can make it possible to feed the world's 8 billion people without destroying our planet.” (21:26)

• Scaling Sustainable Solutions: Ringisen emphasizes the scalability of CRISPR-edited crops, explaining how traits like flood tolerance can be inherited permanently through germline editing, ensuring sustained agricultural benefits.

  “You literally are editing the germline. You're making permanent changes...” (31:41)

• Methane Emissions Reduction: Addressing livestock emissions, Ringisen discusses innovative approaches to reduce methane output from cows by altering their gut microbiome using CRISPR, aiming for nearly zero methane emissions.

  “We are going to add CRISPR directly into the microbiome... to shift the microbiome away from a heavy methane state.” (36:25)

• Carbon Sequestration: The IGI is also pioneering methods to enhance photosynthesis in plants, thereby increasing carbon capture and storage in the soil. This initiative aims to mitigate atmospheric carbon dioxide levels, contributing to global climate goals.

  “We're going to enhance photosynthesis, to capture more carbon, to be able to edit crops...” (38:06)

• Regulatory Challenges: While CRISPR offers unparalleled precision, Ringisen acknowledges the regulatory hurdles, especially in regions like Europe that still classify CRISPR edits as GMOs, despite their precision and safety.

  “Europe is still one of the holdouts that consider those a GMO.” (25:41)

---

Pioneering Predictive Healthcare: Aaron Morris on Implantable Devices

Aaron Morris, an assistant professor of biomedical engineering at the University of Michigan, introduces a novel approach to diagnosing and predicting autoimmune diseases through implantable medical devices.

• The Challenge of Autoimmune Diseases: Morris outlines the difficulties in diagnosing conditions like multiple sclerosis (MS), where traditional methods like MRIs and blood tests are insufficient for early detection and monitoring.

• Innovative Implantable Device: The centerpiece of Morris's research is a sponge-like device implanted under the skin. This device exploits the body’s foreign body response to attract immune cells, which then populate the device. By biopsying the tissue within the implant, doctors can gain detailed cellular and molecular insights into autoimmune conditions.

  “It's just under the skin, so it's very accessible... we can biopsy it and we don't have to worry about causing damage to vital organs.” (43:18)

• Early Prediction and Intervention: In animal trials, the device has successfully predicted the onset of MS before symptoms appear. Early intervention based on these predictions significantly reduced disease manifestation.

  “We dramatically reduced disease. So only one in five animals had any symptoms...” (46:18)

• Future Applications: Morris envisions expanding this technology to monitor multiple diseases simultaneously, allowing for personalized and preventative healthcare. Patients with a family history of autoimmune diseases could opt for implants to monitor their immune systems proactively.

  “Personalized medicine approach would be better enabled by technologies like we're making with these materials...” (52:00)

---

Conclusion: A Biotechnological Future Unfolding

The episode underscores a future where biotechnology, powered by tools like CRISPR and informed by comprehensive projects like the Human Cell Atlas, offers unprecedented capabilities in medicine, agriculture, and environmental stewardship. From personalized cancer treatments and predictive healthcare to climate-resilient crops and carbon sequestration, the innovations discussed promise to address some of the most pressing challenges of our time.

Manoush Zomorodi wraps up by highlighting the rapid pace of these scientific breakthroughs, emphasizing that these advancements are not distant possibilities but ongoing realities that will continue to evolve and impact our lives profoundly.

---

Notable Quotes:

• Aviv Regev: “It's the things we need in order to navigate the human body. If I want to develop a medicine that would only go to the place where something is broken... I need to know how to get there.” (04:11)

• Brad Ringisen: “CRISPR is a tremendously precise tool... changing one gene.” (22:39)

• Aaron Morris: “It's just under the skin, so it's very accessible... we can biopsy it and we don't have to worry about causing damage to vital organs.” (43:18)

---

For a deeper dive into these transformative biotech innovations, visit ted.com to view the full talks by Aviv Regev, Brad Ringisen, and Aaron Morris.

Transcript

[Minouche Zamorodi]

This message comes from Discover, accepted at 99% of places that take credit cards nationwide. If you don't think so, maybe it's time to face facts. You're stuck in the past. Based on the February 2024 Nielsen report. [e-mail] Credit Card this is the TED Radio Hour.

[Unknown Host]

Each week, groundbreaking TED Talks.

[Unknown Speaker]

Our job now is to dream big.

[Unknown Host]

Delivered at TED conferences to bring about.

[Unknown Speaker]

The future we want to see around.

[Unknown Host]

The world to understand who we are. From those talk, we bring you speakers and ideas that will surprise you. You just don't know what you're gonna find challenge you.

[Unknown Speaker]

We truly have to ask ourselves, like.

[Unknown Host]

Why is it noteworthy and even change you? I literally feel like I'm a different person. Yes. Do you feel that way? Ideas worth spreading from Ted and NPR. I'm Minouche Zumarodi. About 25 years ago, the the first draft of the human genome project was completed.

[Brad Ringisen]

We are here to celebrate the completion of the first survey.

[Unknown Host]

Then President Bill Clinton, surrounded by scientists and world leaders.

[Brad Ringisen]

Most wondrous map ever produced by humankind.

[Unknown Host]

Praised the breakthrough project from the podium at the White House.

[Brad Ringisen]

But today's historic achievement is only a starting point.

[Unknown Host]

It took another 20 years to sequence the last 8%. But meanwhile, this genetic map of the human body has led to major breakthroughs in cancer treatments, prenatal testing, and our understanding of rare diseases. It's considered a massive scientific accomplishment. And today, researchers want to go even further.

[Aviv Regev]

So in the human genome project, we only had to handle that genome. But remember, one genome yields many, many, many different kinds of cells.

[Unknown Host]

This is computational biologist Aviv Regev.

[Aviv Regev]

And so instead of just having to map this one static genome, that kind of stays the same throughout the lifespan, when you look at cells, they actually change. My cells today are not the same as the cells that I had 20 years ago or 10 years ago, or the ones that I will have in 10 or 20 years from now.

[Unknown Host]

Aviv is the co founder of a project to map all of the types of cells in the human body. The project is called the Human Cell Atlas. She and researchers all over the world are cataloging how our cells change and interact. The goal is to use it to develop highly personalized medical treatments.

[Aviv Regev]

One of the critical things we need to navigate in the human bodies are diseases. For example, I need an address for a cell if I want to go and target it with a therapy. Biologists have tried to do this for a very long time, but there's about 37.2 trillion cells in an adult human body, and they do different things and behave in different ways. And there's 20,000 genes in the genome, and these genes combine to act in different ways that are not predict. If I know what happens about gene A and I know what happens with gene B, it doesn mean that I can predict what will happen when I put A and B together.

[Unknown Host]

So when you start calculating the number of ways our cells and genome could combine, the possibilities are astronomical.

[Aviv Regev]

Some of the numbers are larger than the numbers of atoms in the universe. So it's big.

[Unknown Host]

But now, thanks to artificial intelligence, scientists can identify all those cells and do these complex calculations.

[Aviv Regev]

That shift can only happen with the AI.

[Unknown Host]

Aviv expects to complete the first draft of the atlas in the next year or so. And she says the old way of understanding cells in the human body compared to the human cell atlas will be like comparing a 15th century map of the world to Google Maps.

[Aviv Regev]

In a Google map you also have many, many layers. So you can look at a Google map, right, and choose the earth view and you see the real topography. Here are the hills, and this is where the water is. But you can also look at a Google map for traffic patterns. And when you have a map like that, you can choose that different level. In order to learn the things that you need to know in order to take the right action. These are the things that we need. We often like to call them atlases because they help us navigate. It's the things we need in order to navigate the human body. If I want to develop a medicine that would only go to the place where something is broken and help that cell function, help that tissue, I need to know how to get there. If you have a map, you have the zip codes. And if you have the zip codes, you can get where you want to get. And if you can get where you want to get, you can deliver a very targeted, very specific therapy that spares the rest of the body and gets only where it needs to go in order to help us be better, those are the kinds of things that you can do with a Google map. And it's very hard to do with a map from the 15th century. And now we have something that's constantly at higher and higher resolution. And so that is extremely rich information for us to navigate.

[Unknown Host]

From mapping every cell in the human body to engineering climate resilient crops, Some of the biggest innovations happening right now are in biotechnology. And that is what we're bringing you today. Ideas and projects at the forefront of this new wave and how these breakthroughs are upending our approach to dise climate Change and our longevity. Back to computational biologist Aviv Regev. Aviv says developing new medications is one of the toughest things for scientists to do. But the human cell atlas makes it much easier. Here she is on the TED stage.

[Unknown Speaker]

Making new medicines is really, really hard. We need to generate the next medicine and then we need to predict the right dose for the right patient. This is not just hard and takes a lot of time. It does takes about 10 years or more to develop a new medicine, but the vast majority of the time it fails. 90% of potential drugs fail in either preclinical research or in clinical trial. You can focus on the fact that it's not happening, but I prefer to think that there's something we can do. What might that be? Well, one of the greatest innovations of our generation are the great advances that have happened in machine learning and AI. They can transform the discovery of medicines. And so in mid 2020, I moved to Genentech to solve this problem. And so every day when I come to work, our patients pictures look at me from our buildings, like Renita here, who is a patient with HER2 positive breast cancer. And like Renita, there are millions and millions of patients who need better medicines. Now, we haven't been idle. For example, we have developed medicines across seven major disease in oncology, in neurology, in rare blood disorders. We run currently 732 clinical trials. Last year alone, 14 million. More than 14 million patients were treated with our medicines. These are successes, but they are successes in a field where the odds against success are 9 to 1. We absolutely have to do better than that.

[Unknown Host]

Explain to me what we can do now and what you see happening in the next five, 10, 20 years.

[Aviv Regev]

Yeah. So, first of all, we use the human cell atlas every single day. We use it to research and discover medicines and to develop medicines. And this is because we ask these questions every day. Which cells in the body use this disease gene? Where could I go in order to target a disease cell but not the healthy cells of the body? What are the unique characteristics of this patient? What happens to cells when we treat with drugs? One of the unique things that we still have to figure out is not just where are the cells, but also the answer to what would happen if I treat this patient? What would happen if I had a therapeutic that inhibits the activity of this gene or of that gene? And those are harder questions to answer.

[Unknown Host]

To answer them, Aviv and her colleagues consult the cell atlas, kind of like you or I might consult ChatGPT, for example. Researchers have been looking at a medication for lung dis that targets particular cells, she can ask the atlas if those same cells show up in other diseases, too.

[Aviv Regev]

We said, we already know that we have a medicine that targets a particular behavior in cells. In what other diseases might we see cells like these? And the answer that we got back was inflammatory bowel disease, ulcerative colitis, and crohn's disease. This was not something we expected at all. It wasn't the direction in which we were originally going to develop this therapeutic. But now we actually have a phase 2 clinical trial in patients based on this finding. That's the kind of stuff that a human cell atlas allows you to do.

[Unknown Host]

You describe it as a lab in a loop. Right. That you're constantly learning and applying your learnings and trying out different sort of medications. Do you mind just walking us through how quickly that can move now that you have this information?

[Aviv Regev]

Yeah. So in the lab, in the loop, you do different kinds of interventions. You go and you poke and you prod cells in different ways. Then you feed that into an algorithm, actually into AI, and you let it build a model of what it thinks is going on. That model might not be necessarily correct, but it is going to make predictions for you. And based on those predictions, you're going to go back and do another experiment and go on and on and on like that. The one that will succeed are the ones that the algorithm learns that worked well. The one that didn't succeed. Also teach the algorithm about what didn't work. Well, it gets better. It makes a new set of predictions, and you iterate and iterate until it is giving you a good enough answer that you can start making an actual medicine from.

[Unknown Speaker]

And that brings us to the final step, which is the patient, the ultimate step for us. But there's many patients in the world, and they're not all the same. And we have to provide the right medicine to the right patient. And sometimes we have to personalize this medicine to the patient. A notable example of that is in cancer. Tumors are different. Every patient's tumor is different. They have a lot of mutations in them. Some of these mutations are entirely private to the patient. These mutations are very important. They are identified by our immune systems, by our T cells in the immune system. They see them in the same way that they see viruses, and they kill the cancer cells. What if, just like a vaccine against a virus, we could devise a vaccine against cancer that would target the immune cells against the cancer cells. But the mutations are private. We need to make the vaccine personalized. Here comes our lab in a loop. We take the patient's tumor, we sequence this, we identify the mutation, and we use a transformer model trained on previous data in order to identify those mutations that would trigger the immune system. We collect a collection of these mutations and we make them into a personalized cancer vaccine just for this patient. And as we treat the patient, we monitor their immune response. We use this information to improve the model for the benefit of all.

[Unknown Host]

I mean, we're talking about the advent finally of really personalized medicine. This is huge, right? Like cancer patients will be able to get a vaccine that nobody else will have. It will be formulated just for them.

[Aviv Regev]

Yeah. Highly personalized medicine that the cancer patient can receive after their diagnosis. And that will trigger the immune system to control the, you know, microscopic tumor that might have remained in the patient's body and that you cannot remove by surgery, resection and so on.

[Unknown Host]

In a moment, Aviv shares how AI and the human cell atlas could go so far as to predict if someone will develop a disease and treat it before it even starts. On the show today, the new wave of biotechnology. I'm Anoush Zamorodi and you're listening to the TED RADIO Hour from npr. We'll be right back. This message comes from NPR sponsor Comcast. Every day, thousands of Comcast engineers and technologists put people at the heart of everything they create. Like Kunle, a Comcast engineer with two teenage boys at home, Kunle thinks about the generation that he is building technology for. This continues to inspire him and his team to build a fast and reliable in home wi fi solution for millions of families like his so everyone can work, learn and play together under one roof. Learn more@comcast corporation.com this message comes from Rei Co Op.

[Unknown Speaker]

Rei believes there are places within yourself you find only outside where you can defy your fears, find your grit and say, I did that. REI has the gear, clothing, glasses and advice to help get you there. Visit your local REI co op or Rei.com this message comes from Capital One. With the Capital One Saver card, earn unlimited 3% cash back on dining and entertainment. Capital One what's in your wallet? Terms apply [e-mail] this message comes from.

[Unknown Host]

NPR sponsor Viking, committed to exploring the world in comfort. Journey through the heart of Europe on an elegant Viking longship with thoughtful service, destination focused dining and cultural enrichment on board and onshore. And every Viking voyage is all inclusive with no children and no casinos. Discover [e-mail] the it's the TED Radio Hour from NPR. I'm Minouche Zamarodi on the show today, the new wave of biotechnology. And we were just talking to Aviv Regev, one of the founders of the Human Cell Atlas project, a mapping of every type of human cell and how they interact with genes. Aviv is now working at Genentech, where she and other scientists are applying this new knowledge to create personalized medical Imagine a vaccine formulated just for you based on your genetic and cellular profile. But her other goal is to predict and prevent disease from developing in the first place. Can I ask you about the future of preventative care? One of the things or one of the teams working on the Cell Atlas has produced a blueprint of how human skeletons form in utero. And one of them found that certain genes were activated early bone cells that might be linked to an increased risk of developing hip arthritis as an adult. So I guess I'm wondering, you know, when you, in the future, when your baby is born, will a doctor be saying, okay, well, based on what we know about your newborn, they have these sorts of proclivities towards these diseases. So make sure you get these vitamins and make sure you get this sort of vaccine. At this point, you know, we won't even have to develop the diseases because we'll nip them in the bud because we know the blueprint.

[Aviv Regev]

Yes, there are huge diagnostic and prognostic opportunities, not just when you already have disease, but also well ahead of them. And there is a lot to say about that. The first actually starts with human genetics, which is the ability to look at your genome and assess some of your risk. We already know that we can assess the risk for some really serious conditions which are really driven by a single gene. For example, if you have a certain mutation in your BRCA1 gene, then your risk of breast cancer is substantially increased, and it changes how your doctor will monitor you and how you will be cared for throughout your life. But now we can actually look across information from a lot of our genes combined together. This is actually something known as the polygenic risk score. And for certain diseases, you can start making these assessments for people who have especially substantially increased risk. And I think this would be fantastic because most of our focus has been on looking at disease after it already exists. This gives so many opportunities for preventative care.

[Unknown Host]

I guess. Could you just paint a picture for us about how you think the field of medicine and biotechnology will be different for the patient in the long term? 20 years, 30 years, 40 years? What sort of mindset will we have as people when we think of how to treat illnesses that we were born with or develop over time.

[Aviv Regev]

I think it's a great question. I'm not gonna put a timeline on it, but I do think things will change substantially for patients. There are so many patients who are treated on medicines and then they don't bring them benefit. We believe that there would be a great reduction in that pattern and that will come from being able to predict a lot better which patient will benefit from which medicine so that we can come in a much more fine way rather than with broad strokes. This understanding of the cells and their internal mechanisms opens up so many possibilities. There's also going to be earlier disease treatment and even preventative disease treatment that today is simply not possible if you cannot predict that the disease will develop and you cannot provide treatment for it. But if you can and you can understand the early, early mechanisms of what happens in that disease, then you can imagine providing this therapy for the patient. We're also going to see, I believe, therapies that are one and done more, more cure rather than continuous care. We're going to see this also with a much broader range of vaccines that can be used. Those are things that do not exist yet and you can never tell exactly when they will exist, how impactful they would be. But it is really exciting prospects for us going forward. And while I talk about it in the future tense, this is what people are doing right now and it's getting better every year. Actually it's getting better every six months. It's actually a scientific breakthrough that is happening right now.

[Unknown Host]

That's Aviv Regev. She is the Executive Vice president and head of Research and Early development at Genentech and the co founder of the Human Cell Atlas Project. You can see her full [e-mail] on the show today. How a new wave of biotechnology could change our lives, including what we eat. In the 1990s, genetically modified foods or GMOs hit the market. Scientists developed these crops to make them more resistant to weeds and insects and to be more hardy so that farmers could yield more of them. But GMOs were controversial.

[Unknown Speaker]

Anti GM activists stormed the field about a month ago.

[Unknown Host]

To be sure, humans have been cross breeding plants for thousands of years. But to some, the idea of messing with the genes of organisms that they would eat sounded dangerous. There were worries that GMOs would cause allergies or antibiotic resistance or other long term health effects.

[Unknown Speaker]

For you and for me. Is this stuff safe to eat?

[Unknown Host]

Today concerns remain about cross contamination with wild species or farmers relying on GMO seeds that can withstand Herbicides and pesticides. The consensus on the whole though, is that GMOs are just as safe as non GMO foods to eat, which is why you don't hear much about genetically modified food these days. That might be about to change because of crispr.

[Brad Ringisen]

The beauty is, is that this is a technology that can work on human cells, it can work on microorganisms, bacteria, and it can work on plants.

[Unknown Host]

This is Brad Ringisen. He's a physical chemist and head of the Innovative Genomics Institute. Brad says the gene editing tool CRISPR could make it possible to feed the world's 8 billion people without destroying our planet in the process.

[Brad Ringisen]

I think when you hear CRISPR for climate, people sometimes sort of shake their head and they don't understand the impact that this amazing technology has to help stabilize food supply into the future.

[Unknown Host]

So I'm old enough to remember when GMO or genetically modified crops were introduced and there was in Europe especially, a huge uproar about this idea of genetically changing plants, seeds so that they are resistant to insects, to heat, all those sorts of things. How is CRISPR different than what's been used for the last three or so decades?

[Brad Ringisen]

So this is a really important question, and the good news is, is that CRISPR is a tremendously precise tool. I think people don't understand that nature itself produces genetic changes, and that's been occurring over generations and generations of all plants in the world. But GMOs specifically really have very uncontrolled genomic changes. They're changes throughout the entire genome. And oftentimes you're doing this in a way that is not very precise. Most of the food that we eat, at least in the United States for sure, are very high yielding crops called hybrid crops. Several decades ago, during the Green Revolution, people realized that you could actually cross two parents, two distinct, different, genetically distinct parents, and the offspring actually have better traits, better yields, much, much higher yields than the parents did. And those are all just genetic changes that have resulted that dramatically increase yields. Well, the problem is that when those seeds from hybrid crops are planted, the next generation, you see changes then in the genome of those seeds, because the parents, some of the mix up of genes that have occurred don't translate into that next generation. So people do not plant hybrid seeds into the next generation. So they have to go back to the seed suppliers and buy the seeds every single year. So if you enter CRISPR into this equation now, the beauty of CRISPR is that you can go into a very controlled location on the genome and make one very Small change in some cases just at the base pair level where you're really just making one very small change, you're maybe just turning off a gene. In many cases you can actually have a disease resistant crop, for instance, where you're just changing one gene. And that's a very precise way to make controlled changes. And at least in the United States and in countries like India and many countries in Africa and South and Central America, these changes that I was just talking about, if it's done with CRISPR, actually are not considered GMOs from a regulation standpoint. So there's actually a very fast tracked way to be able to get these CRISPR products to market around the world.

[Unknown Host]

Okay. So legally the law is, is understands the difference. I was reading about a barley trial that began in, in spring of 2024 in Switzerland where they were, they're testing to see if CRISPR can increase barley grain yields. But you know, in Switzerland they are not GMO friendly. And so this, this field is enclosed by an electric fence. It is patrolled by security and a guard dog.

[Brad Ringisen]

Yeah, I think there is a lot of misunderstanding and Europe is still one of the, one of the holdouts that they consider even CRISPR edits, those precise edits that I talked about that could occur in nature. Europe is one of the sole holdouts that still consider those a gmo. And the regulatory aspect of that is very, very difficult in a place like Europe. But look, I've talked with the Danish Ag Minister, I've talked with Danish Dairy Farm and when I talk about CRISPR with the agricultural aspects in places like Germany and Denmark, the agricultural ministers are very much in support of this technology because they understand the climate implications and the greenhouse gas emissions and the threat to food security. And so they're pushing the European Union to make changes and they want to make those changes in support of sustainability. There's just so much impact that you can have on the world to potentially feed billions of people using this technology to do it in a sustainable way.

[Unknown Speaker]

I became the Executive Director of the Innovative Genomics Institute, the IGI in 2020.

[Unknown Host]

Here's Brad Ringisen on the TED stage.

[Unknown Speaker]

The same year that our founder Jennifer Doudna won the Nobel Prize in Chemistry for her pioneering work in crispr. That's right. Let's go, Jennifer. I was drawn to the IGI as a place where CRISPR could be applied to help improve the lives of nearly every person in the world, to help create a sustainable future. The work to improve food security is already underway. Our scientists at the IGI can already edit over 30 different crops. Rice, wheat, broccoli, sunflowers, tomatoes. We're even trying to develop crops that can persist against emerging pathogens by knocking out disease susceptibility genes or create drought tolerant crops by reducing the number of pores that are on the water, losing pores on their leaves. We're even trying to save the banana and chocolate from emerging pathogens.

[Unknown Host]

So the idea is that you take a particular crop and you edit the genes so that they are more climate friendly, so that they grow more heartily without using resources. Is it that simple?

[Brad Ringisen]

Yeah, well, I mean, nothing's ever simple in science. But yes, the concept is indeed that simple. And you know, Jennifer and I have developed sort of a climate strategy at the ig. And the first leg of that strategy is that we are looking at areas of the world that are on the front lines of climate change. So I just got back from a big trip to India where I met with a lot of agricultural scientists and government officials in India. Look, they have to feed nearly 1.4 billion people. And they're seeing a tremendous threat to their food supply. They're seeing it from heat, they're seeing it from drought, they're seeing it from floods, they're seeing it from salinity as there's a storm. If you're growing food on the coastline, you now have to deal with ocean water that has contaminated your soils. And so what I learned in that trip to India was that it's becoming very much more difficult to predict what those threats to their food supply are going to be. There used to be traditional areas that were drought prone, traditional areas that were flood prone. And now what they're seeing is a very large degree of uncertainty. And in some of those drought ridden areas, they're seeing floods, and in some of the flood areas they're seeing droughts. They're seeing temperatures of 50 degrees Celsius or higher. And you know, life is just not meant to live. Plants are not meant to live at those temperatures, which really puts a lot of stress and strain on the food supply. And that's just one country. You're seeing this around the globe. And so what we're going to do in sort of that first leg of our climate strategy is use CRISPR to really try to build in resilience of these crops that we all eat to survive.

[Unknown Host]

So producing climate resilient crops. Tell me more about that, what that looks like.

[Brad Ringisen]

Well, one of our partners, Pam Ronald, who just won the Wolf Prize a couple years ago at UC Davis has worked with many collaborators to develop a flood tolerant rice. And you would say, oh, well, rice sometimes grows underwater? Well, yeah, it grows underwater in a controlled way. But if you have a storm that comes in, or several storms that come in, and those rice plants are submerged for one week, two week, three weeks, traditional rice crops cannot survive. And so Pam's rice variety is now being grown by millions of farmers in Southeast Asia. And what you see are, I've seen pictures of farmers so proud of being able to grow this crop because they're standing next to a flooded field. And guess what? Pam's variety looks beautiful. It's this lush green field of rice. And then on the side of the traditional crop, you see a rice field that's just sort of decimated by the flood. So I think there's a real potential to scale this, because one thing that biology does is scale very well. If you can generate seeds, the farmers will put those seeds in that can guarantee yields, that can guarantee things like flood tolerance or temperature tolerance. And I really do think that we can scale quickly and ultimately it helps the citizens of the world.

[Unknown Host]

And the rice that is then grown, having already been edited, are the seeds that come from that rice pre edited, so to speak?

[Brad Ringisen]

Yes. That's the beauty of this, is that you literally are editing the germline. You're making permanent changes so that the generations and the seeds would be able to have the same traits.

[Unknown Host]

I was reading about these researchers in Florida who had edited sugar cane, that as a result the sugarcane leaves would grow at a different angle and collect more sunlight, which was amazing. So they were stronger.

[Brad Ringisen]

So this is one of the big challenges, is that all of these require genetic changes. So this concept of stacking changes, taking large amounts of genetic or genomic information and putting them into a single crop is going to be really, really important. So can you change those branching angles? Can you provide flood tolerance? Can you provide heat toler and put them all together? Because I think one thing that is guaranteed in climate change and in the coming decades is that there's going to be more uncertainty. There's going to be vast oscillation of storms. One year you might have drought, the next year you might have too much rain, the next year it might be disease. And so one thing that certainty of sort of certainty of uncertainty, I think means that you're going to have to stack these desirable traits in a minute.

[Unknown Host]

More with Brad Ringisen on how CRISPR is a tool for dealing with climate change in other ways. From altering the microbiome of cows to boosting photosynthesis in plants. On the show today, the new wave of Biotechnology. I'm Anoush Zamarodi and you are listening to the TED Radio Hour from npr. Are Stick with us.

[Unknown Speaker]

Support for this podcast and the following message come from E Trade from Morgan Stanley. With E Trade, you can dive into the market with easy to use tools, $0 commissions and a wide range of investments. And now there's even more to love. Get access to industry leading research and insights from Morgan Stanley to help guide your decisions. Open an account and get up to $1,000 or more with a qualifying deposit. Get started [e-mail] terms and other fees apply. Investing involves risks. Morgan Stanley Smith Barney LLC Member SIPC E Trade is a business of Morgan Stanley. This message comes from BetterHelp. Therapy can be expensive, but at BetterHelp they believe therapy should feel accessible, not like a luxury. Which is why they offer quality care at a price that makes sense and can help you with anything from anxiety to everyday stress. Your mental health is worth it and now it's within reach. Visit betterhelp.com NPR to get 10% off your first month. That's betterhelp.com NPR this message comes from NPR sponsor Disney season one of Andor had critics calling it the best Star wars series yet. Now season two of the Emmy nominated series returns April 22nd. Follow Cassian Andor as he embarks on a path from a rebel to a hero, starring Diego Luna. And from creator Tony Gilroy, writer of Michael Clayton and the bourne identity. Season two of Andor is streaming April 22nd only on Disney.

[Minouche Zamorodi]

This message comes from Pemco Mutual Insurance Company. You know that moment when things take an unexpected turn and you get that sudden sinking feeling that maybe it could have been avoided? Pemco Insurance wants to help you avoid that feeling by sharing prevention tips that empower you to prevent some of life's preventable pitfalls. Because Pemco's commitment to their customers goes beyond the moment of acclaim, it's about being with their customers every day. [e-mail] prevention.

[Unknown Host]

It'S the TED Radio Hour from NPR. I'm Minouche Zumarodi. On the show today, the new wave of biotechnology, and we were just talking to Brad Ringisen from the Innovative Genomics Institute about how scientists are using CRISPR to develop crops and livestock that can withstand, even help us deal with climate change. I think most of us, you know, have heard we should eat less meat because livestock are huge emitters. We have had scientists on the show to talk about different feed that they're trying to develop to reduce the emissions that come out of all those cattle burps and the other end, too. But this is a different approach with crispr.

[Brad Ringisen]

Yeah, it is. And I think I want to say, first of all, that we need all approaches. I think the single biggest question that I get when I start talking about cows and livestock methane emissions is they say, brad, why. Why aren't we just pushing vegetarian diets and meat alternatives and cultured meat to move away from cows? And my answer is we need all solutions, But I think we can't ignore the fact that global meat consumption and global beef consumption specifically, are still increasing around the world. So Jennifer and I have made this a priority inside the institute. Our goal at the IGI is to eliminate methane emissions. We believe that CRISPR can be used in the cow rumen to affect, not the cow cells. We're not talking about cow breeding here. We're not talking about, you know, genetically modified cows. We are going to add CRISPR directly into the microbiome, what's called the rumen, the gut of the cow, to shift the microbiome away from a heavy methane state. And I believe, based on the experiments that I've been seeing, that we can actually create an alternative state of that microbiome where there is almost no methane being emitted. And I think that that's an exciting, really big stretch goal that we have for the igi.

[Unknown Host]

Okay, so we have talked about crops and livestock emitting less, higher yields, but the third application you're working on is using CRISPR to remove carbon from the atmosphere and put it into soil.

[Brad Ringisen]

That's right. That's right. And I really do believe that it's. That is a very scalable solution to carbon dioxide removal.

[Unknown Speaker]

This brings me to my plan to help remove atmospheric carbon and return it to ag soils. And we think it's a perfect place to put carbon because those soils have already lost close to 500 gigatons of carbon dioxide equivalents since humans have started farming. What if we could use CRISPR to help put this carbon back? It would help achieve global climate goals, but it would also let farmers help work in marginal and underutilized lands and convert those into more fertile soils, helping to reduce the need for deforestation. It's a win, win, win. So our plan is to enhance photosynthesis, to capture more carbon, to be able to edit crops, to be able to create roots that grow deeper and more dense to push carbon into the soil, and then ultimately work with that Soil microbiome to be able to keep that carbon and have it stay put in the soil. Now, even with all that carbon that photosynthesis absorbs every year, it's actually a pretty inefficient process. But IGI scientists think we can edit those crops to improve both the way plants absorb light energy and the way that they build biomass to help improve the efficiency of photosynthesis by up to 30%. That's more carbon for food and more carbon to store.

[Unknown Host]

So this idea of capturing carbon with plants, that's exciting. But what do you see as the next steps to getting consumed? Tumors on board. Because a lot of people are still very skeptical about GMOs. So where do we go from here?

[Brad Ringisen]

Yeah, I think the biggest thing is that people understand that genetic modification is not a bad word. It's not unsafe. It's not something that has ever been proven to produce a product or food that is unsafe. And then when you add CRISPR and genome editing into this equation, it's an even more precise tool. It's a tool that can help speed innovation. It's a tool that can help feed the world in the face of a rapidly changing climate. And it can be done in a very sustainable way. Much more so sustainable than using chemical fertilizers and spraying pesticides. We're going to be doing this in a much, much more natural way, and I'm very excited to. To try to keep pushing this over the next decade.

[Unknown Host]

That was Brad Ringisen. He's a physical chemist and the executive director of the Innovative Genomics Institute. You can see his full [e-mail] so we have talked about gene editing, artificial intelligence, and the human cell atlas. But there are all sorts of other techniques that scientists are currently developing. And so now we want to focus on one particular biotech tool that may help doctors diagnose and even predict autoimmune disorders. This is when the body attacks itself.

[Unknown Speaker]

For example, psoriasis is an autoimmune disease that results in, like, flaky, itchy skin. That's usually diagnosed by looking at somebody's skin. Right. It's a rash. You can see it. But many of these diseases are much more difficult to diagnose.

[Unknown Host]

Aaron Morris is an assistant professor of biomedical engineering at the University of Michigan.

[Unknown Speaker]

One that we study a lot in my lab is multiple sclerosis. Multiple sclerosis is an autoimmune disease that affects the brain and the spinal cord. So it's much more difficult to diagnose. You know, you can't Just look at it. And although you could potentially take a biopsy, nobody wants you to take a biopsy of their brain or spinal cord. And you certainly can't do it repeatedly, right? It's dangerous, it's painful.

[Unknown Host]

Blood tests aren't helpful for diagnosing Ms. Erin says MRIs not really either.

[Unknown Speaker]

On an MRI, you can see lesions, so you can see spots if somebody has Ms. That indicate that there's been some damage. But it doesn't give you cellular or molecular information about the disease. It's a spot on an image. By the time you have a big spot, a lot of damage is already done. In many of the conditions that we're talking about, you are monitoring symptoms. And if someone is showing symptoms, it may have already caused substantial damage.

[Unknown Host]

So to help doctors diagnose autoimmune diseases, Aaron's research is adding to the growing world of implantable medical devices.

[Unknown Speaker]

The device itself looks a lot like a sponge. About the size of like a pencil.

[Unknown Host]

Eraser, this tiny device may help doctors detect disease from within the body.

[Unknown Speaker]

And when you talk about putting this under someone's skin, it's barely noticeable somewhere, sort of by the hip, perhaps on the arm or on the wrist.

[Unknown Host]

So here's how it works. When the device is implanted under a patient's skin, the body sends immune cells to attack it. This is called the foreign body response.

[Unknown Speaker]

It's basically the body's response to try to protect itself from what it sees as something that is foreign and potentially dangerous.

[Unknown Host]

Usually this is a problem for doctors. It's a reason why an implant like a heart stent might fail. But the foreign body response is exactly what's making Aaron's device work.

[Unknown Speaker]

It's highly porous. And we actually think that porosity is really, really important for its ability to have blood vessels form throughout it and fill up with tissue.

[Unknown Host]

When those immune cells arrive, they fill up that sponge like device, forming new tissue. Doctors can take that tissue and diagnose an autoimmune disease like Ms.

[Unknown Speaker]

The idea is it's just under the skin, so it's very accessible, it's easy to get to. But it's also not a vital tissue. Right? So it's not performing some essential function for somebody. It's not their brain or their heart. It's something that we made. They don't need it. And so we can biopsy it and we don't have to worry about causing damage to vital organs.

[Unknown Host]

I mean, that's really cool. Instead of you going to get the tissue, you get the tissue to Come to you?

[Unknown Speaker]

That's a pretty good way of putting it, yeah.

[Unknown Host]

Are the cells that show up to the implant going to be the same ones that are showing up, let's say, with Ms. @ the brain and the spine? Like, how do you know that they're the same thing that's happening in the places that are having problems?

[Unknown Speaker]

Your inkling is probably right that it's not entirely reflective of what's happening in the brain and the spinal cord. For example, your brain has tissue resident immune cells called microglia that aren't coming to our implant. They live in the brain, they don't leave the brain. And so those aren't part of our implants, but they are involved in Ms. So we're not creating a perfect mimic of the brain in someone's arm, but it does contain information that's reflective of disease.

[Unknown Host]

Aaron says that being able to monitor the immune system will be helpful for something called relapsing, remitting ms, where patients go through periods of worsening symptoms followed by remission.

[Unknown Speaker]

If we know somebody's about to relapse, we might be able to give them a stronger drug for a short period of time to prevent that relapse from happening.

[Unknown Host]

But more than just diagnosing and monitoring diseases, Aaron is hoping that this technology predicts them before they develop. His device has not been tested in humans yet, but he and his team have found promising results in animal trials.

[Unknown Speaker]

We did a study where we predicted the development of the mouse model of Ms. Before they had any symptoms.

[Unknown Host]

Then they gave, gave the mice preemptive treatment.

[Unknown Speaker]

When we were able to predict and then intervene with drugs, we dramatically reduced disease. So only one in five animals had any symptoms of disease when we did that, as opposed to all of them having symptoms of disease if we didn't.

[Unknown Host]

Do you envision a scenario where someone who doesn't have a disease gets one of these implants as well? I guess maybe because someone in their family had it and they think genetically they're predisposed or, I don't know, would that ever happen?

[Unknown Speaker]

That wouldn't be our first indication. But I do think eventually people would want to use this for that more preventative kind of approach. An example would be if you have a first degree relative that has, say, type 1 diabetes, you have approximately a 15 fold increased risk of developing type 1 diabetes yourself. For MS, it's something like five to tenfold. So it would be a personal decision. Do you, you know, do you want some monitor to be able to help you predict if you're going to develop one of these conditions. Another example of this would be if you have one autoimmune disease, approximately 25% of patients with one autoimmune disease will develop another one, a comorbid autoimmune disease. So those patients, you know, they're at very high risk for developing a second autoimmune condition. And if we're able to monitor for multiple of these different kinds of conditions, they might really want the ability to do that. The pie in the sky idea is we have already been exploring how far we can take this. What conditions can we analyze. So at this point, we've looked at models of multiple sclerosis, type 1 diabetes, organ transplant rejection, and even metastatic cancers. And so our hope is if you can monitor, you know, dozens of different disease, it's now a very attractive proposition to have one of these implanted because sure, your risk of any individual one is low, but in aggregate it's much higher.

[Unknown Host]

I do think people are getting more used to this idea of monitoring like on their smartphones, what's going on in their bodies. The examples I'm thinking of are, I know people who have diabetes, who are, have a constant glucose monitor going and they can check in and it'll ping them to tell them, you know, if they're, make sure they don't forget their insulin. Is that sort of what you see being the future for people, that this starts to just become normal? You have something that's in your body and it's giving you information.

[Unknown Speaker]

That is very much what I think the future of monitoring these autoimmune diseases might look like. Those implantable glucose monitors can be life saving for diabetic patients. A similar analogy is many people wear all sorts of activity trackers that are tracking their heart rate, tracking their sleep. That's certainly a rapidly growing area that sort of massive amounts of data that people are collecting, collecting on themselves. And I think knowing what your immune system is doing is something that these systems can't yet do. But if paired with technology like we're developing, perhaps they could. And there might be a lot of utility in that data.

[Unknown Host]

Just Aaron, telescope out for us, like, you know, let's say this all goes according to plan. What, what could the field of medicine look like when it comes to diagnosing and treating autoimmune diseases? Let's say, you know, five, ten years from now.

[Unknown Speaker]

My hope is that we'll be able to better care for patients so we'll know that somebody is developing a disease and we'll be able to intervene before they have symptoms or we'll know someone's about to have a relapse and we'll be able to prevent it. We know that preventive medicine is better than treating once somebody is sick. The technologies that we're making, we're very interested in using them to better diagnose and better monitor patients. But that's not all that they're useful for. So they give you cellular and molecular information about disease. That cellular and molecular information is really helpful when you're thinking about designing and developing new treatments for disease. Right now, when we want to develop new treatments, we do a lot of work in animal models, but it would be nice to know what the detailed molecular pathologies are in humans. We have some of this information, but we don't have a complete picture. And some of the reason we don't have a complete picture is the same problem as it is with the diagnostics. It's really hard to get that information. How do you get the information about dynamics of cell. Cell interactions in someone's brain? And we've actually shown in an animal model of Ms. That we're able to dig in and really look at how cells are communicating with each other. And we can use that to get a detailed picture of the cellular and molecular changes of disease that we can target with therapies.

[Unknown Host]

And we're learning more that. But every single person has their own special soup of different molecules and biomarkers and how they live, their environment, combined with their genetics, combined with we don't even know what. Right. So is there a way to sort of tailor it to each individual as well?

[Unknown Speaker]

You're absolutely right. So every individual is different. They have different genetics. Unless they have an identical twin, they're exposed to different things. So as somebody goes about their day, they might encounter chemicals or something else in the atmosphere. There's of course, lifestyle choices. So everybody's different. We talk about personalized medicine and can we create specific therapies for specific people? And I definitely think that personalized medicine approach would be better enabled by technologies like we're making with these materials that are able to help us better monitor monitor disease.

[Unknown Host]

That was Aaron Morris. He's an assistant professor at the University of Michigan, where he heads the Precision Immune Microenvironments lab. You can see his full [e-mail] thank you so much for listening to the show. This episode was produced by Rachel Faulkner White, Katie monteleone and Kai McNamee. It was edited by Sanaz Mesh Kinpour, Katie Monteleone and me. Our production staff at NPR also includes James Delahusy, Harsha Nahada and Fiona Guerin. Our executive producer is Irene Noguchi. Our audio engineers were Gilly Moon and Simon Jensen. Our theme music was written by Ramtin Arablouei. Our partners at TED are Chris Anderson, Roxanne Hylash, Alejandra Salazar and Daniela Balarezzo. I'm Manoush Zamorodi and you have been listening to the TED Radio Hour from npr.

[Unknown Speaker]

This message comes from NPR Sponsor A New Perspective on Performance Apparel. Check out the latest dream Knit collection by visiting viori.com NPR for 20% off your first purchase. Exclusions apply. Visit the website for full terms and conditions. This message comes from Tourism Australia. Australia, a land of contrast where white sand beaches are almost as plentiful as flat white coffees and where you can go away for a vacation yet somehow feel right at home. Explore [e-mail] this message comes from Synchrony.

[Minouche Zamorodi]

Bank who can help you get your do nothing savings off the couch and working hard. No more sleeping late and eating all the chips. Time to start earning your keep in a big way with their High Yield Savings account that has a great rate, easy access to your funds and no monthly fees or minimum balance requirements. Put your lazy savings to work. Go to synchrony.com NPR member FDIC.